Property:Side Effects / Interactions
This is a property of type Text.
U
Uthaipaisanwong et al. (2020): Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study +
According to data, no serious side effects in ginger-group or differences to placebo (p>0.05, not significant) +
Uthaipaisanwong et al. (2020): Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study +
According to data, no serious side effects in placebo-group or differences to ginger (p>0.05, not significant) +
Uysal et al. (2016): Effects of foot massage applied in two different methods on symptom control in colorectal cancer patients: Randomised control trial +
NI +
Uysal et al. (2016): Effects of foot massage applied in two different methods on symptom control in colorectal cancer patients: Randomised control trial +
NI +
Uysal et al. (2016): Effects of foot massage applied in two different methods on symptom control in colorectal cancer patients: Randomised control trial +
NI +
V
Van Zandwijk et al. (2000): EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer +
Typical: mucocutaneous side effects (dryness, desquamation, itching, bleeding, hair loss), symptoms of the digestive tract (especially dyspepsia)
Severe side effects (grade 3/4)
- Gastrointestinal: 47
- Skin: 43
- Malaise: 1
- Temporary increase in liver enzymes: 3
- Hypercholesterolemia 3
- Bone pain 2
- Other: 8 +
Van Zandwijk et al. (2000): EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer +
Typical: mucocutaneous side effects (dryness, desquamation, itching, bleeding, hair loss)
Severe side effects (grade 3/4)
- Gastrointestinal: 32
- Skin: 50
- Malaise: 5
- Temporary increase in liver enzymes: 2
- Hypercholesterolemia: 2
- Bone pain: 2
- Other: 15 +
Van Zandwijk et al. (2000): EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer +
Typical: symptoms of the digestive tract (especially dyspepsia)
Severe side effects (grade 3/4)
- Gastrointestinal: 44
- Skin: 11
- Malaise: 2
- Temporary increase in liver enzymes: 1
- Other: 3 +
Van Zandwijk et al. (2000): EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer +
NA +
Villani et al. (2016): Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial +
NI +
Villani et al. (2016): Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial +
NI +
Vitale et al. (2020): ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy +
Not separated between arms
Only general indication of good tolerability +
Vitale et al. (2020): ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy +
Only general indication of good tolerability
Not separated between arms +
W
Walsh et al. (2010): Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma +
NA +
Walsh et al. (2010): Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma +
No side effects +
Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer +
NI +
Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer +
NI +
Wrbka et al. (1987): Unterstützung der Chemotherapie inoperabler Karzinome durch proteolytische Fermente +
Treatment with Wobe Mugos E:
Tolerance of microclysms (67 patients in the evaluation): 87.3% of patients with good tolerance, 4 patients with sphincter weakness and limited ability to administer, 12.7% of patients with discontinuation due to gastrointestinal side effects
Tolerance of dragées (58 patients in the evaluation): 71.4% of patients with good tolerance, 28.6% of patients with discontinuation; in 27% of patients, intake could not be assessed due to unauthorised discontinuation or incorrect information
Tolerance of local intrapleural application (33 patients in the evaluation): 96.9% of patients with good tolerance, 3.1% of patients with discontinuation +